
Bevacizumab Biosimilars Reduce Costs While Maintaining Survival Outcomes in mCRC
A real-world, economic evaluation based on a population-based retrospective cohort study in Ontario, Canada, found that prescribing bevacizumab biosimilars Mvasi and Zirabev as first-line treatments for patients with metastatic colorectal cancer (mCRC) …